Back to Results

GT Biopharma Inc (GTBP)

GT Biopharma Inc (NASDAQ: GTBP) is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies built around its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager, or Dual Targeting TriKE, platforms. Its development pipeline includes GTB-3650, a phase 1 candidate being studied for CD33-positive myeloid leukemias, GTB-5550, a phase 1 dose-escalation basket trial candidate targeting B7-H3 in advanced solid tumors, and GTB-7550, a preclinical program being evaluated for lupus and other autoimmune disorders. The company, which was formerly known as OXIS International, changed its name to GT Biopharma in July 2017. Incorporated in 1965, it is based in San Francisco, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-GTBP
$6.54
-8.9% Downside
Fair
$75
944.6% Upside
Bargain
Weak
0.0%
November 13, 2026
3.6x
12.955 M
7.996 M
0.0%
94.2%
-182.0
-4.8%
126.8%
Valuation • Fair Value

GT Biopharma Inc (NASDAQ-GTBP) Fair Value by Valuation Model

Review the available estimates for GT Biopharma Inc (NASDAQ-GTBP), including Comps Fair Value.

Primary Valuation Read

Fair Value

$6.54

Estimated downside of 8.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$6.54

Comparable-company valuation reference.

Analyst Price Target

$75

Analysts imply upside of 944.6%.

How to read these valuation models

Use the 4 available valuation references for GT Biopharma Inc (NASDAQ-GTBP) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for GT Biopharma Inc (NASDAQ-GTBP)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review GT Biopharma Inc (NASDAQ-GTBP) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for GT Biopharma Inc (NASDAQ-GTBP)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-182.0

Lower score that deserves closer risk review.

FCF / Net Income

126.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for GT Biopharma Inc (NASDAQ-GTBP). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for GT Biopharma Inc (NASDAQ-GTBP)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

52

Dividend Yield

0.0%

No current dividend yield is indicated.

Payout Ratio

-4.8%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for GT Biopharma Inc (NASDAQ-GTBP), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

GT Biopharma Inc (NASDAQ-GTBP) Stock Forecast & Technical Outlook

Review GT Biopharma Inc (NASDAQ-GTBP) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for GT Biopharma Inc (NASDAQ-GTBP) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for GT Biopharma Inc (NASDAQ-GTBP) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for GT Biopharma Inc (NASDAQ-GTBP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for GT Biopharma Inc (NASDAQ-GTBP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for GT Biopharma Inc (NASDAQ-GTBP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for GT Biopharma Inc (NASDAQ-GTBP)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, GT Biopharma Inc (NASDAQ-GTBP) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

GT Biopharma Inc (NASDAQ-GTBP) Stock FAQ

Data-supported answers about GT Biopharma Inc (NASDAQ-GTBP), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$6.54
Estimated downside 8.9%
Valuation Rating
Overvalued
Estimated downside of 8.9%
Analyst Target
$75
Implied upside 944.6%
Financial Health
Weak
Current financial-health read

The current fair value estimate for GT Biopharma Inc (NASDAQ-GTBP) is $6.54. This implies an estimated downside of 8.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 8.9% versus the current market price.

The available analyst price target for GT Biopharma Inc (NASDAQ-GTBP) is $75. The analyst target implies estimated upside of 944.6%.

The current financial health read for GT Biopharma Inc (NASDAQ-GTBP) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for GT Biopharma Inc (NASDAQ-GTBP) is November 13, 2026.

The latest available data indicates no current dividend yield for GT Biopharma Inc (NASDAQ-GTBP).

The current market capitalization listed for GT Biopharma Inc is 12.955 M.

The current enterprise value listed for GT Biopharma Inc is 7.996 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for GT Biopharma Inc is NASDAQ-GTBP, and the stock is listed on NASDAQ.

GT Biopharma Inc (NASDAQ-GTBP) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for GT Biopharma Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for GT Biopharma Inc is 94.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B